journal
MENU ▼
Read by QxMD icon Read
search

Lancet Respiratory Medicine

journal
https://read.qxmd.com/read/30987857/precision-medicine-in-obstructive-sleep-apnoea
#1
REVIEW
Miguel Angel Martinez-Garcia, Francisco Campos-Rodriguez, Ferrán Barbé, David Gozal, Alvar Agustí
Obstructive sleep apnoea (OSA) is a heterogeneous and complex disease; however, diagnosis and management still rely on a simple set of tools and few therapeutic options. Precision medicine has emerged as the next goal for clinical practice, with the objective being to offer individually tailored treatments. Ways of implementing precision medicine in clinical practice have emerged for various respiratory disorders, and such an approach could also be readily exported to OSA. Here, we propose a control panel tool that describes OSA in four domains: disease severity, biological activity, impact on the patient, and pathophysiological traits...
April 12, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30981696/alectinib-versus-crizotinib-in-untreated-asian-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-alesia-a-randomised-phase-3-study
#2
Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se-Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N Morcos, You Lu, Li Zhang
BACKGROUND: Anaplastic lymphoma kinase-positive (ALK-positive) disease occurs in approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence reported in Asian patients. This study is the first phase 3 randomised trial recruiting only Asian patients to compare alectinib with crizotinib as a first-line treatment for ALK-positive non-small-cell lung cancer with 600 mg of alectinib twice per day. This study assessed consistency of the progression-free survival benefit with the global phase 3 ALEX study...
April 10, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30975495/functional-effects-of-the-microbiota-in-chronic-respiratory-disease
#3
REVIEW
Kurtis F Budden, Shakti D Shukla, Saima Firdous Rehman, Kate L Bowerman, Simon Keely, Philip Hugenholtz, Darius P H Armstrong-James, Ian M Adcock, Sanjay H Chotirmall, Kian Fan Chung, Philip M Hansbro
The composition of the lung microbiome is increasingly well characterised, with changes in microbial diversity or abundance observed in association with several chronic respiratory diseases such as asthma, cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. However, the precise effects of the microbiome on pulmonary health and the functional mechanisms by which it regulates host immunity are only now beginning to be elucidated. Bacteria, viruses, and fungi from both the upper and lower respiratory tract produce structural ligands and metabolites that interact with the host and alter the development and progression of chronic respiratory diseases...
April 8, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30962167/dust-to-dust
#4
Coreen McGuire
No abstract text is available yet for this article.
April 5, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30962166/the-true-scale-of-artisanal-mining
#5
Talha Khan Burki
No abstract text is available yet for this article.
April 5, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30962165/emergency-mdi-and-spacer-packs-for-asthma-and-copd
#6
Duncan Keeley, Martyn R Partridge
No abstract text is available yet for this article.
April 5, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30956061/an-insider-view-on-the-world-symposium-on-pulmonary-hypertension
#7
Marc Humbert, Nazzareno Galiè, Vallerie V McLaughlin, Lewis J Rubin, Gérald Simonneau
No abstract text is available yet for this article.
April 4, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30948347/machine-learning-molecular-classification-in-ipf-uip-or-not-uip-that-is-the-question
#8
Simon Hart
No abstract text is available yet for this article.
April 1, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30948346/use-of-a-molecular-classifier-to-identify-usual-interstitial-pneumonia-in-conventional-transbronchial-lung-biopsy-samples-a-prospective-validation-study
#9
Ganesh Raghu, Kevin R Flaherty, David J Lederer, David A Lynch, Thomas V Colby, Jeffrey L Myers, Steve D Groshong, Brandon T Larsen, Jonathan H Chung, Mark P Steele, Sadia Benzaquen, Karel Calero, Amy H Case, Gerard J Criner, Steven D Nathan, Navdeep S Rai, Murali Ramaswamy, Lars Hagmeyer, J Russell Davis, Umair A Gauhar, Daniel G Pankratz, Yoonha Choi, Jing Huang, P Sean Walsh, Hannah Neville, Lori R Lofaro, Neil M Barth, Giulia C Kennedy, Kevin K Brown, Fernando J Martinez
BACKGROUND: In the appropriate clinical setting, the diagnosis of idiopathic pulmonary fibrosis (IPF) requires a pattern of usual interstitial pneumonia to be present on high-resolution chest CT (HRCT) or surgical lung biopsy. A molecular usual interstitial pneumonia signature can be identified by a machine learning algorithm in less-invasive transbronchial lung biopsy samples. We report prospective findings for the clinical validity and utility of this molecular test. METHODS: We prospectively recruited 237 patients for this study from those enrolled in the Bronchial Sample Collection for a Novel Genomic Test (BRAVE) study in 29 US and European sites...
April 1, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30935882/interstitial-lung-abnormalities-ignotum-per-ignotius
#10
Katerina M Antoniou, Vasilios Tzilas, Eirini Vasarmidi, Emmanouil K Symvoulakis, Argyris Tzouvelekis, Demosthenes Bouros
No abstract text is available yet for this article.
March 29, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30935881/increased-monocyte-count-as-a-cellular-biomarker-for-poor-outcomes-in-fibrotic-diseases-a-retrospective-multicentre-cohort-study
#11
Madeleine K D Scott, Katie Quinn, Qin Li, Robert Carroll, Hayley Warsinske, Francesco Vallania, Shirley Chen, Mary A Carns, Kathleen Aren, Jiehuan Sun, Kimberly Koloms, Jungwha Lee, Jessika Baral, Jonathan Kropski, Hongyu Zhao, Erica Herzog, Fernando J Martinez, Bethany B Moore, Monique Hinchcliff, Joshua Denny, Naftali Kaminski, Jose D Herazo-Maya, Nigam H Shah, Purvesh Khatri
BACKGROUND: There is an urgent need for biomarkers to better stratify patients with idiopathic pulmonary fibrosis by risk for lung transplantation allocation who have the same clinical presentation. We aimed to investigate whether a specific immune cell type from patients with idiopathic pulmonary fibrosis could identify those at higher risk of poor outcomes. We then sought to validate our findings using cytometry and electronic health records. METHODS: We first did a discovery analysis with transcriptome data from the Gene Expression Omnibus at the National Center for Biotechnology Information for 120 peripheral blood mononuclear cell (PBMC) samples of patients with idiopathic pulmonary fibrosis...
March 29, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30935880/can-monocytes-predict-prognosis-of-idiopathic-pulmonary-fibrosis
#12
Michael Kreuter, Toby M Maher
No abstract text is available yet for this article.
March 29, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30930110/a-role-for-psychosocial-support-in-the-management-of-respiratory-disorders
#13
Priya Venkatesan
No abstract text is available yet for this article.
March 28, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30930109/legionella-transmission-through-cooling-towers-towards-better-control-and-research-of-a-neglected-pathogen
#14
Anne Paschke, Ulrich E Schaible, Wolfgang Hein
No abstract text is available yet for this article.
March 28, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30922878/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer-impower150-key-subgroup-analyses-of-patients-with-egfr-mutations-or-baseline-liver-metastases-in-a-randomised-open-label-phase-3-trial
#15
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi, Gene Finley, Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin, Mark A Socinski
BACKGROUND: The IMpower150 trial showed significant improvements in progression-free and overall survival with atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient subgroups. METHODS: IMpower150 was a randomised, open-label, phase 3 study done at 240 academic medical centres and community oncology practices across 26 countries worldwide...
March 25, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30922877/searching-for-a-chemoimmunotherapy-signal-in-patients-with-non-small-cell-lung-cancer-and-egfr-mutations
#16
Jose M Pacheco, D Ross Camidge
No abstract text is available yet for this article.
March 25, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30910543/the-microbiome-and-tuberculosis-state-of-the-art-potential-applications-and-defining-the-clinical-research-agenda
#17
REVIEW
Charissa C Naidoo, Georgina R Nyawo, Benjamin G Wu, Gerhard Walzl, Robin M Warren, Leopoldo N Segal, Grant Theron
The diverse microbial communities within our bodies produce metabolites that modulate host immune responses. Even the microbiome at distal sites has an important function in respiratory health. However, the clinical importance of the microbiome in tuberculosis, the biggest infectious cause of death worldwide, is only starting to be understood. Here, we critically review research on the microbiome's association with pulmonary tuberculosis. The research indicates five main points: (1) susceptibility to infection and progression to active tuberculosis is altered by gut Helicobacter co-infection, (2) aerosol Mycobacterium tuberculosis infection changes the gut microbiota, (3) oral anaerobes in the lung make metabolites that decrease pulmonary immunity and predict progression, (4) the increased susceptibility to reinfection of patients who have previously been treated for tuberculosis is likely due to the depletion of T-cell epitopes on commensal gut non-tuberculosis mycobacteria, and (5) the prolonged antibiotic treatment required for cure of tuberculosis has long-term detrimental effects on the microbiome...
March 22, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30885621/the-nasopharyngeal-microbiome-and-lrtis-in-infants
#18
Geraint B Rogers
No abstract text is available yet for this article.
March 15, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30885620/bacterial-and-viral-respiratory-tract-microbiota-and-host-characteristics-in-children-with-lower-respiratory-tract-infections-a-matched-case-control-study
#19
Wing Ho Man, Marlies A van Houten, Marieke E Mérelle, Arine M Vlieger, Mei Ling J N Chu, Nicolaas J G Jansen, Elisabeth A M Sanders, Debby Bogaert
BACKGROUND: Lower respiratory tract infections (LRTIs) are a leading cause of childhood morbidity and mortality. Potentially pathogenic organisms are present in the respiratory tract in both symptomatic and asymptomatic children, but their presence does not necessarily indicate disease. We aimed to assess the concordance between upper and lower respiratory tract microbiota during LRTIs and the use of nasopharyngeal microbiota to discriminate LRTIs from health. METHODS: First, we did a prospective study of children aged between 4 weeks and 5 years who were admitted to the paediatric intensive care unit (PICU) at Wilhelmina Children's Hospital (Utrecht, Netherlands) for a WHO-defined LRTI requiring mechanical ventilation...
March 15, 2019: Lancet Respiratory Medicine
https://read.qxmd.com/read/30898521/ventilation-before-intubation-how-to-prevent-hypoxaemia
#20
Jonathan D Casey, Matthew W Semler
No abstract text is available yet for this article.
March 14, 2019: Lancet Respiratory Medicine
journal
journal
47869
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"